Bi‐specific antibodies directed against CD123 on AML LSC include, among others, the CD123/CD3 DART flotetuzumab, the CD123/CD3 bi‐specific IgG1 antibody JNJ‐63709178, and the CD123‐targeting bi‐specific antibody XmAb14045.82 This evidence concerns the gene IL3RA and acute myeloid leukemia.